Big Take23 Joulu 2022

Declining ALS Patients Are Waiting On The FDA's Next Move

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon and especially insidious form of ALS that runs in families. Patients are urging the US Food and Drug Administration to speed access to the drug, which hasn’t yet been approved because clinical trials didn’t conclusively show it works.

As pharmaceutical companies use new technologies to seek cures of all kinds, this tension between making sure drugs are effective and safe, and offering not-quite-ready but possibly life-saving treatment to people for whom it’s now or never, is becoming more acute.

Bloomberg’s chief medical writer Robert Langreth joins this episode to talk about the race to find a treatment for ALS–and the back and forth between patients, companies and government regulators. We also hear the story of a Pennsylvania family that has passed on a gene for ALS from generation to generation–and their demands for access to the new treatment.

Learn more about the episode here: https://bloom.bg/3WIkvCm

Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK

Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.

See omnystudio.com/listener for privacy information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(1012)

Could Bond Yields Break the Stock Market?

At over 5%, the 10-year Treasury yield is the highest since 2007. Those soaring yields are raising lots of questions about whether investors should be trimming stocks and buying bonds. But timing such...

28 Syys 17min

Weekend Listen: There's a Mind-Boggling Number of Rich People in America

In 2014, the economists Owen Zidar and Eric Zwick were asked by the US Treasury to conduct a study on the tax burden of private business owners. One of their central findings is that there are about t...

27 Syys 59min

Crafting America’s Favorite Countertops Is Killing Workers

People who fabricate artificial stone are getting sick with a deadly chronic illness—on that, there’s no debate. But whether it’s the individual shops or the material’s manufacturers who should be hel...

25 Syys 21min

This Isn’t Your Grandparents’ UN

At this week’s UN General Assembly meeting in New York, an AI executive delivered dire warnings via video. President Trump threatened to annihilate Iran. China’s Xi Jinping skipped the meeting altoget...

24 Syys 15min

Why Everyone Is Talking About High Diesel Prices

Diesel prices are hitting new highs, and voters aren’t happy. With the midterms approaching, the Trump administration is trying to find ways to curb fuel costs, including a potential US diesel export ...

23 Syys 17min

US-China AI Race to Take Center Stage at Trump-Xi Meeting

As Chinese President Xi Jinping makes his first visit to Washington in over a decade, trade and the AI race will likely dominate talks with Donald Trump. On today’s Big Take Asia podcast, host K. Oanh...

22 Syys 16min

How Much Is the Hormuz Blockade Costing the US?

The Iran War is likely to take center stage when President Trump meets with Gulf leaders on the sidelines of this week's UN General Assembly. Houthi attacks in Saudi Arabia and rising energy prices un...

21 Syys 14min

Big Pharma Needs New Drugs. China Has Them

American pharma giants are increasingly turning to Chinese labs to discover, test and develop cutting-edge drugs. On the Big Take Asia podcast, Bloomberg’s Amber Tong and Robert Langreth join Oanh Ha ...

20 Syys 17min